Phase 1 Alzheimer's Disease Trial, Not Yet Recruiting

Parts I and II (Healthy Volunteer Sections):

• People with a significant history or current condition affecting the heart, lungs, liver, kidneys, blood, digestive system, hormones, immune system, skin, nervous system, or mental health, or any other condition the investigating doctor considers a safety risk.
• People whose blood or urine test results at screening or on the day before dosing suggest a significant underlying health condition.
• People who show signs of suicidal thoughts as assessed by a standard screening tool at the screening visit or the day before dosing, or who have a history of a suicide attempt at any point in their life.
• People who test positive for Hepatitis B, Hepatitis C, or HIV at screening.
• People who have smoked cigarettes or used other nicotine-containing products in the three months before screening.
• People who have regularly consumed alcohol in the six months before the trial, defined as more than 20 units per week for men or more than 16 units per week for women (where one unit equals 8g of ethanol).
• People who test positive for alcohol, nicotine, or drugs of abuse in a urine test at screening or on the day before dosing begins.
• People with a history of drug abuse (as defined by standard psychiatric diagnostic criteria) within the two years before entering the study.
• People who have taken part in another clinical trial or received an investigational medicine within 90 days before the first dose of the trial medication.
• People who have lost 500 mL or more of blood (roughly one unit) within 90 days before the first dose of the trial medication.
• People whom the investigating doctor considers unsuitable for the trial for any other reason.

Part III (Alzheimer's Disease Section):

• People with a history or current presence of any uncontrolled systemic disease, such as high blood pressure (systolic at or above 150 mmHg or diastolic at or above 100 mmHg) or diabetes with an HbA1c level at or above 8% at screening.
• People with a history or current presence of unstable or significant heart, kidney, or liver disease (for example, a previous heart attack).
• People with any active or unstable significant medical or psychiatric condition, as determined by the investigating doctor.
• People with serious or unstable illnesses affecting the liver, kidneys, digestive system, breathing, heart, hormones, nervous system (other than Alzheimer's disease), immune system, or blood, or any other condition the investigating doctor believes could interfere with assessing the trial's safety or effectiveness.
• People who have evidence of a condition other than Alzheimer's disease that may affect thinking and memory, such as other forms of dementia, stroke, brain injury, autoimmune conditions (such as multiple sclerosis), or infections that have affected the nervous system.
• People with a history of a primary or returning cancer within the past five years, with the exception of certain treated skin cancers, treated cervical cancer in situ, or treated prostate cancer in situ with a normal result on a specific marker test after treatment.
• People with a history of bleeding in the brain, a brain aneurysm, abnormal blood vessels in the brain, blocked carotid artery, stroke, or epilepsy.
• People who show signs of suicidal thoughts as assessed by a standard screening tool at the screening visit or the day before dosing, or who have a history of a suicide attempt at any point in their life.
• People who test positive for Hepatitis B, Hepatitis C, or HIV at screening.